Phathom Pharmaceuticals (NASDAQ:PHAT) Coverage Initiated at Stifel Nicolaus

Stifel Nicolaus started coverage on shares of Phathom Pharmaceuticals (NASDAQ:PHAT - Free Report) in a report issued on Friday, MarketBeat.com reports. The firm issued a buy rating and a $24.00 price target on the stock.

Separately, Needham & Company LLC restated a buy rating and set a $26.00 price objective on shares of Phathom Pharmaceuticals in a research note on Friday, April 26th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average target price of $22.00.

Phathom Pharmaceuticals Stock Performance

Shares of Phathom Pharmaceuticals stock traded up $0.28 during trading on Friday, hitting $10.04. The company's stock had a trading volume of 647,291 shares, compared to its average volume of 814,006. The company has a fifty day simple moving average of $9.79 and a two-hundred day simple moving average of $8.68. The company has a market capitalization of $587.54 million, a PE ratio of -2.59 and a beta of 0.67. Phathom Pharmaceuticals has a 52 week low of $6.07 and a 52 week high of $17.02.

Phathom Pharmaceuticals (NASDAQ:PHAT - Get Free Report) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.80) earnings per share for the quarter, beating analysts' consensus estimates of ($0.92) by $0.12. The firm had revenue of $0.68 million for the quarter, compared to the consensus estimate of $0.93 million. During the same quarter in the prior year, the business posted ($1.33) earnings per share. As a group, analysts predict that Phathom Pharmaceuticals will post -4.22 EPS for the current year.

Insider Buying and Selling

In other Phathom Pharmaceuticals news, insider Terrie Curran sold 16,851 shares of Phathom Pharmaceuticals stock in a transaction that occurred on Friday, March 22nd. The shares were sold at an average price of $9.11, for a total transaction of $153,512.61. Following the transaction, the insider now owns 410,784 shares of the company's stock, valued at $3,742,242.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Phathom Pharmaceuticals news, insider Terrie Curran sold 16,851 shares of Phathom Pharmaceuticals stock in a transaction that occurred on Friday, March 22nd. The shares were sold at an average price of $9.11, for a total transaction of $153,512.61. Following the transaction, the insider now owns 410,784 shares of the company's stock, valued at $3,742,242.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Molly Henderson sold 3,435 shares of Phathom Pharmaceuticals stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $11.10, for a total transaction of $38,128.50. Following the transaction, the chief financial officer now directly owns 95,263 shares in the company, valued at approximately $1,057,419.30. The disclosure for this sale can be found here. 24.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Phathom Pharmaceuticals

Several large investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. increased its position in Phathom Pharmaceuticals by 355.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,626 shares of the company's stock worth $60,000 after purchasing an additional 5,171 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Phathom Pharmaceuticals by 371.4% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,429 shares of the company's stock worth $87,000 after purchasing an additional 6,641 shares during the last quarter. DAVENPORT & Co LLC bought a new stake in Phathom Pharmaceuticals in the fourth quarter worth $91,000. Public Employees Retirement System of Ohio bought a new stake in Phathom Pharmaceuticals in the third quarter worth $92,000. Finally, Klingman & Associates LLC bought a new stake in Phathom Pharmaceuticals in the first quarter worth $110,000. Institutional investors own 99.01% of the company's stock.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.